Omeros Corporation (OMER) News
Latest headlines that mention OMER, newest first · each headline opens the original publisher
- Last price
- $16.26
- Day change
- -1.75%
- Next earnings
- 2026-11-12
OMER headlines
latest coverageYartemlia generated $32.2M in gross sales during its first full quarter on market.
Omeros stock rocketed to a five-year high Thursday on blowout second-quarter results for its new treatment for transplant complications. The post This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why appeared first on Investor's Business Daily .
Heartflow boasts rapid AI-driven growth but faces reimbursement headwinds, while Omeros bets everything on its first commercial launch.
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.
Image source: The Motley Fool. Tuesday, March 31, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
Image source: The Motley Fool. Wednesday, May 13, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading
OMER news alerts
Get an alert by email or push when a new headline mentions OMER.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.